Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director | June 02, 2026 | June 04, 2026 |
| Inogen IncINGN · Entity 2083 | Director | June 05, 2026 | June 09, 2026 |
| KESTRA MEDICAL TECHNOLOGIES, LTD.KMTS · Entity 4686 | Director | September 08, 2026 | September 11, 2026 |
| NOVANTA INCNOVT · Entity 3857 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 111,263 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 111,263 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs vested on June 2, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,146 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs vested on June 2, 2026.
F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
Inogen Inc
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 104,966 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 28,081 · Balance 104,966 F1: The reported shares were acquired pursuant to a restricted stock unit award. Subject to the reporting person's continued service, the restricted stock unit award shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were acquired pursuant to a restricted stock unit award. Subject to the reporting person's continued service, the restricted stock unit award shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant.
KESTRA MEDICAL TECHNOLOGIES, LTD.
Report date September 08, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 37,507 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Sale · Disposed 3,908 · Balance 37,507 F1: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.4300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. F3: Includes 17,512 Common Shares received from West Affum Holdings, L.P., in a pro rata distribution exempt pursuant to Rule 16a-9. |
| Common SharesSEC Table I · non-derivative | Direct | 44,724 |
Reported balance
After 2026-09-09 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-09 · Grant · Acquired 7,217 · Balance 44,724 F4: The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.
F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.4300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.
F3: Includes 17,512 Common Shares received from West Affum Holdings, L.P., in a pro rata distribution exempt pursuant to Rule 16a-9.
F4: The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date.
NOVANTA INC
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,897 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Exercise / conversion · Acquired 1,325 · Balance 1,897 F1: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Exercise / conversion · Disposed 1,325 · Balance 0 F1: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,799 |
Reported balance
After 2026-01-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-02 · Grant · Acquired 1,799 · Balance 1,799 F2: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F3: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares.
F2: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date).
F3: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Hill-Rom Holdings, Inc.
Report date December 13, 2021 · Filed December 15, 2021
Section 16 reporting ended · disclosed 2021-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 1
1 source rowRow 1 · 2021-12-13 · Disposition to issuer · Disposed 2,284 · Balance 0 F1: Disposed of pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter (the "Merger Agreement") in exchange for a cash payment of $156.00 per share of common stock. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $103.11 · Expires 2029-11-06 | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-13 · Disposition to issuer · Disposed 4,102 · Balance 0 F2: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 6, 2020, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.14 · Expires 2030-11-11 | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-13 · Disposition to issuer · Disposed 6,054 · Balance 0 F3: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 11, 2021, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. |
| Performance-Based Restricted Stock Units (11/06/2019)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-13 · Disposition to issuer · Disposed 3,947 · Balance 0 F4: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F5: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level. |
| Performance-Based Restricted Stock Units (11/11/2020)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-12-13 · Disposition to issuer · Disposed 4,092 · Balance 0 F4: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F6: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level. |
| Restricted Stock Units (11/06/2019)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-12-13 · Disposition to issuer · Disposed 664 · Balance 0 F7: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F8: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. |
| Restricted Stock Units (11/11/2020)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-13 · Disposition to issuer · Disposed 1,363 · Balance 0 F7: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F9: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. |
| Restricted Stock Units (11/10/2021)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-12-13 · Disposition to issuer · Disposed 6,708 · Balance 0 F7: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F10: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter (the "Merger Agreement") in exchange for a cash payment of $156.00 per share of common stock.
F2: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 6, 2020, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.
F3: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 11, 2021, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock.
F4: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock.
F5: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level.
F6: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level.
F7: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock.
F8: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock.
F9: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock.
F10: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2026 Filed Sep 11, 2026 00:25 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | GrantCommon Shares | 7,217 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-388297 · ownership.xml · nonDerivative · entry 2 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,724 F4 · shares: The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date. F4 · price: The reported securities represent restricted stock units which each entitle the reporting person to receive one common share of the Issuer. The restricted stock units will vest on September 9, 2027, subject to the reporting person's continued service through such date. Read SEC document |
| September 08, 2026 Filed Sep 11, 2026 00:25 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | SaleCommon Shares | 3,908 | $25.20 | $98,464.40 |
DisclosureSEC source: 0001193125-26-388297 · ownership.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,507 F1 · kind: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2 · price: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.4300. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. F3 · balance_after: Includes 17,512 Common Shares received from West Affum Holdings, L.P., in a pro rata distribution exempt pursuant to Rule 16a-9. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:19 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 28,081 | $0.00 | $0.00 |
DisclosureSEC source: 0001760737-26-000005 · ownership.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,966 F1 · shares: The reported shares were acquired pursuant to a restricted stock unit award. Subject to the reporting person's continued service, the restricted stock unit award shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant. Read SEC document |
| June 03, 2026 Filed Jun 4, 2026 20:46 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 25,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001760737-26-000004 · wk-form4_1780606000.xml · derivative · entry 3 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,146 Underlying: Class A Common Stock · 25,146 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:46 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001760737-26-000004 · wk-form4_1780606000.xml · derivative · entry 2 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2026. F2 · derivative.expiration_date: The RSUs vested on June 2, 2026. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:46 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001760737-26-000004 · wk-form4_1780606000.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:48 UTC | NOVANTA INC NOVT · Entity 3857 | GrantRestricted Stock Units · Derivative | 1,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001076930-26-000011 · form4.xml · derivative · entry 3 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,799 Underlying: Common Stock · 1,799 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grant Date (or, if such date is not a business day, on the first business day immediately following the first anniversary of the Grant Date). F3 · derivative.exercise_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. F3 · derivative.expiration_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:48 UTC | NOVANTA INC NOVT · Entity 3857 | Exercise / conversionRestricted Stock Units · Derivative | 1,325 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001076930-26-000011 · form4.xml · derivative · entry 2 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,325 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:48 UTC | NOVANTA INC NOVT · Entity 3857 | Exercise / conversionCommon Stock | 1,325 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001076930-26-000011 · form4.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On January 2, 2026, the RSUs were settled in Novanta Inc. common shares. Read SEC document |
| September 04, 2025 Filed Sep 8, 2025 21:45 UTC | KESTRA MEDICAL TECHNOLOGIES, LTD. KMTS · Entity 4686 | GrantCommon Shares | 10,909 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-113637 · ownership.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,903 F1 · shares: The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date. F1 · price: The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 4, 2026, subject to the Reporting Person's continued service through such date. F2 · balance_after: Includes 12,994 restricted common shares of the Issuer that were automatically converted in connection with the Issuer's initial public offering from Class A Common Units of West Affum Holdings, L.P. previously held by the Reporting Person which were originally granted on October 7, 2024. The restricted common shares vest into common shares of the Issuer. 4,331 restricted common shares will vest on October 7, 2025, 4,331 restricted common shares will vest on October 7, 2026 and 4,332 restricted common shares will vest on October 7, 2027. Read SEC document |
| July 11, 2025 Filed Jul 14, 2025 20:39 UTC | NOVANTA INC NOVT · Entity 3857 | Exercise / conversionRestricted Stock Units · Derivative | 572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019140 · form4.xml · derivative · entry 2 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 572 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On July 11, 2025, the RSUs were settled in Novanta Inc. common shares. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On July 11, 2025, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On July 11, 2025, the RSUs were settled in Novanta Inc. common shares. F1 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On July 11, 2025, the RSUs were settled in Novanta Inc. common shares. Read SEC document |
| July 11, 2025 Filed Jul 14, 2025 20:39 UTC | NOVANTA INC NOVT · Entity 3857 | Exercise / conversionCommon Stock | 572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-019140 · form4.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") was the economic equivalent of one Novanta Inc. common share. On July 11, 2025, the RSUs were settled in Novanta Inc. common shares. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000305 · wk-form4_1749086994.xml · derivative · entry 3 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,282 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000305 · wk-form4_1749086994.xml · derivative · entry 2 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2025. F2 · derivative.expiration_date: The RSUs vested on June 2, 2025. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:30 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000305 · wk-form4_1749086994.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2025 Filed May 16, 2025 23:39 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 30,612 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-073842 · ownership.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,885 F1 · shares: The reported shares were acquired pursuant to a restricted stock unit award. Subject to the reporting person's continued service, the restricted stock unit award shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:56 UTC | NOVANTA INC NOVT · Entity 3857 | GrantRestricted Stock Units · Derivative | 1,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-000800 · form4.xml · derivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,325 Underlying: Common Stock · 1,325 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grante Date (or, if such date is not a business day, on the first business date immediately following the first anniversary of the Grant Date). F1 · derivative.exercise_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grante Date (or, if such date is not a business day, on the first business date immediately following the first anniversary of the Grant Date). F2 · derivative.exercise_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. F1 · derivative.expiration_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grante Date (or, if such date is not a business day, on the first business date immediately following the first anniversary of the Grant Date). F2 · derivative.expiration_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. Read SEC document |
| July 11, 2024 Filed Jul 15, 2024 20:06 UTC | NOVANTA INC NOVT · Entity 3857 | GrantRestricted Stock Units · Derivative | 572 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-24-020378 · form4.xml · derivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 572 Underlying: Common Stock · 572 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grante Date (or, if such date is not a business day, on the first business date immediately following the first anniversary of the Grant Date). F1 · price: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grante Date (or, if such date is not a business day, on the first business date immediately following the first anniversary of the Grant Date). F1 · derivative.exercise_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grante Date (or, if such date is not a business day, on the first business date immediately following the first anniversary of the Grant Date). F2 · derivative.exercise_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. F1 · derivative.expiration_date: Each Restricted Stock Unit represents the right to receive one Novanta Inc. common share on the first anniversary of the Grante Date (or, if such date is not a business day, on the first business date immediately following the first anniversary of the Grant Date). F2 · derivative.expiration_date: The Restricted Stock Units were fully vested and non-forfeitable on the Grant Date. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:43 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 1,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000305 · wk-form4_1718747025.xml · derivative · entry 2 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,814 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The 1,814 RSUs vested on June 16, 2024. F2 · derivative.expiration_date: The 1,814 RSUs vested on June 16, 2024. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:43 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 1,814 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000305 · wk-form4_1718747025.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:26 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000286 · wk-form4_1718313968.xml · derivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,493 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 00:44 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000267 · wk-form4_1718153069.xml · derivative · entry 2 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 7, 2024. F2 · derivative.expiration_date: The RSUs vested on June 7, 2024. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 00:44 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000267 · wk-form4_1718153069.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 21:16 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 21,871 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070879 · ownership.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,273 F1 · shares: The reported shares wee acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting schedule. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:34 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 1,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000051 · primary_doc.xml · derivative · entry 2 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,814 Underlying: Class A Common Stock · 1,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: 1,813 RSUs vested on June 16, 2023. The remaining 1,814 RSUs shall vest and become exercisable on June 16, 2024, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: 1,813 RSUs vested on June 16, 2023. The remaining 1,814 RSUs shall vest and become exercisable on June 16, 2024, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:34 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 1,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000051 · primary_doc.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 23:08 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000039 · primary_doc.xml · derivative · entry 3 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,400 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 23:08 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000039 · primary_doc.xml · derivative · entry 2 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 6, 2023. F2 · derivative.expiration_date: The RSUs vested on June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 23:08 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000039 · primary_doc.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,461 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:31 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 17,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034061 · doc4.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,402 F1 · shares: The reported shares were acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant, or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting date. Read SEC document |
| June 17, 2022 Filed Jun 23, 2022 00:39 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023639 · doc4.xml · derivative · entry 3 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,648 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 16, 2022 Filed Jun 23, 2022 00:39 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 1,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023639 · doc4.xml · derivative · entry 2 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,627 Underlying: Class A Common Stock · 1,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The remaining RSUs shall vest and become exercisable in two approximately equal installments on June 16, 2023 and June 16, 2024, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The remaining RSUs shall vest and become exercisable in two approximately equal installments on June 16, 2023 and June 16, 2024, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 16, 2022 Filed Jun 23, 2022 00:39 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A common stock | 1,813 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023639 · doc4.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:44 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 6,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036052 · doc4.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,308 F1 · shares: The reported shares were acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant, or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting date. Read SEC document |
| March 22, 2022 Filed Mar 25, 2022 01:02 UTC | Inogen Inc INGN · Entity 2083 | GrantCommon Stock | 459 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021015 · doc4.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459 F1 · shares: The reported shares wee acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) May 10, 2022, or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting schedule. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:41 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerRestricted Stock Units (11/10/2021) · Derivative | 6,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013222 · marketforms-54638.xml · derivative · entry 8 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,708 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F10 · price: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger. F10 · derivative.exercise_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger. F10 · derivative.expiration_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 11, 2022, were assumed by Baxter in the merger and converted into a number of restricted stock units granted by Baxter, that relate to shares of Baxter common stock, determined by multiplying the number of restricted stock units by the quotient obtained by dividing (A) 156.00 by (B) the average closing price, rounded down to the nearest cent, per share of Hill-Rom Holdings, Inc. common stock on the New York Stock Exchange for the consecutive period of ten (10) trading days immediately preceding (but not including) the last trading day prior to the closing date of the merger. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:41 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerRestricted Stock Units (11/11/2020) · Derivative | 1,363 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013222 · marketforms-54638.xml · derivative · entry 7 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,363 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F9 · price: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. F9 · derivative.exercise_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. F9 · derivative.expiration_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 12, 2021, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:41 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerRestricted Stock Units (11/06/2019) · Derivative | 664 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013222 · marketforms-54638.xml · derivative · entry 6 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 664 shares Expires not disclosed F7 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F8 · price: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. F8 · derivative.exercise_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. F8 · derivative.expiration_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting in three equal installments beginning November 7, 2020, were cancelled in exchange for a cash payment of $156.00 per unvested share of underlying common stock. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:41 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerPerformance-Based Restricted Stock Units (11/11/2020) · Derivative | 4,092 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013222 · marketforms-54638.xml · derivative · entry 5 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,092 shares Expires not disclosed F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F6 · price: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level. F6 · derivative.exercise_date: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level. F6 · derivative.expiration_date: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 11, 2020, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 187.5% of the target performance level. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:41 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerPerformance-Based Restricted Stock Units (11/06/2019) · Derivative | 3,947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013222 · marketforms-54638.xml · derivative · entry 4 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,947 shares Expires not disclosed F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F5 · price: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, these performance-based restricted stock units, which were granted November 6, 2019, were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock and applicable performance conditions were deemed to be achieved at 146.0% of the target performance level. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:41 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 6,054 | $61.86 Strike: $94.14 | $374,500.44 |
DisclosureSEC source: 0001214659-21-013222 · marketforms-54638.xml · derivative · entry 3 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,054 shares Expires 2030-11-11 F3 · price: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 11, 2021, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 11, 2021, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:41 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 4,102 | $52.89 Strike: $103.11 | $216,954.78 |
DisclosureSEC source: 0001214659-21-013222 · marketforms-54638.xml · derivative · entry 2 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,102 shares Expires 2029-11-06 F2 · price: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 6, 2020, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, these options, which provided for vesting in four equal installments beginning on November 6, 2020, were cancelled in exchange for a cash payment representing the difference between $156.00 and the exercise price of each share of underlying common stock. Read SEC document |
| December 13, 2021 Filed Dec 15, 2021 20:41 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Disposition to issuerCommon Stock | 2,284 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-013222 · marketforms-54638.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter (the "Merger Agreement") in exchange for a cash payment of $156.00 per share of common stock. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 20:15 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionRestricted Stock Units (11/11/2020) · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-011930 · marketforms-54276.xml · derivative · entry 3 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,346 Underlying: Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: RSUs were granted on November 11, 2020 and vested 34% on November 12, 2021; 33% will vest on November 12, 2022 and 33% will vest on November 12, 2023. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. F3 · derivative.expiration_date: RSUs were granted on November 11, 2020 and vested 34% on November 12, 2021; 33% will vest on November 12, 2022 and 33% will vest on November 12, 2023. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 20:15 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Tax withholdingCommon Stock | 253 | $155.11 | $39,242.83 |
DisclosureSEC source: 0001214659-21-011930 · marketforms-54276.xml · nonDerivative · entry 2 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,284 F2 · kind: Reflects the reporting person's payment of minimum statutory tax obligations by withholding shares of Hill-Rom Holdings, Inc. common stock incident to the vesting of RSUs in accordance with Rule 16b-3. Read SEC document |
| November 12, 2021 Filed Nov 16, 2021 20:15 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionCommon Stock | 700 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-21-011930 · marketforms-54276.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 17:30 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,018 | $0.00 Strike: $94.14 | $0.00 |
DisclosureSEC source: 0001214659-21-011621 · marketforms-54242.xml · derivative · entry 4 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,054 Underlying: Common Stock · 2,018 shares Expires 2030-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options vested, or will vest, 25% on each of November 11, 2021, 2022, 2023 and 2024. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 17:30 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | SaleCommon Stock | 2,018 | $155.14 | $313,072.52 |
DisclosureSEC source: 0001214659-21-011621 · marketforms-54242.xml · nonDerivative · entry 2 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,837 F1 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 6, 2021. Read SEC document |
| November 11, 2021 Filed Nov 12, 2021 17:30 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | Exercise / conversionCommon Stock | 2,018 | $94.14 | $189,974.52 |
DisclosureSEC source: 0001214659-21-011621 · marketforms-54242.xml · nonDerivative · entry 1 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2021 Filed Nov 12, 2021 17:30 UTC | Hill-Rom Holdings, Inc. HRC · Entity 132395 | GrantRestricted Stock Units (11/10/2021) · Derivative | 6,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001214659-21-011621 · marketforms-54242.xml · derivative · entry 3 Ladone Mary Kay · CIK 0001760737 · SVP, Corp. Dev., Strat. & IR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,708 Underlying: Common Stock · 6,708 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: RSUs vest 34% on November 11, 2022, 33% on November 11, 2023 and 33% on November 11, 2024. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. F3 · derivative.expiration_date: RSUs vest 34% on November 11, 2022, 33% on November 11, 2023 and 33% on November 11, 2024. RSUs will automatically be converted into shares of common stock on the date indicated and are entitled to dividend equivalent rights which accrue on dividend record dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.